Activation of cellular immunity, mainly cytotoxic T cells, plays an important role in the · mechanisms of cyclic acute exacerbation of hepatocellular damage (AE ) in hepatitis B virus (HBV) carriers. Monitoring of the dynamics of immunoreactivity is clinically important to manage the patients and recognize the mechanism of liver damage . Serum neopterin has been " 'ideh-recognized as a marker of actiyation of cell-mediated immunity. We obseryed the clinical course of fin~ hepatitis Be antigen I HBeAg ) positiye HBY carriers with recurrent AE for mean eighteen months b,' m o nitoring of serum neo pterin using a RIA kit. Alanine amino transferase (ALT) and HBeAg ,yere .lbo m e .l~ured serialh' as markers for hepatocne necrosis and viral replication, respecti\'el~: During follow-up period. eaLh patient had se"eral episodes of A£ alternating with normal or nearly normal li"er function. The le,'els of serum neopterin changed dynamically related to those of HBeAg and ALT Temporal analysis of these makers before, during and after the episodes of AE showed a close involvement of the "iral replication prior to the hepatocellular injury as well as the activation of cellular immunity following the viral replication. Immunological monitoring of serum neopterin could provide useful information about the dynamic interaction between virus replication, cellular immunoreactivity and hepatocellular damage. It was thought that serum neopterin can be used as a complementary marker to follow and manage chronic hepatitis B patients.
Introduction
Hepatitis B virus (HBV) is a DNA virus that replicates in infected hcpatocytes by reverse transcrip§Address for correspondence : Osaka Medical College, First Deparunent of Internal Medicine, Daigaku-cho 2-7, Takaruski, Osaka 569-8686, Japan. Tel. 0726-83-1221 , F<Lx. 0726-83-1801 tion similar to the process of retroviruses (1). HBV causes transient and chronic infection, the latter mainly caused by the vertical transmission from a mother to her infant.
This chronic infaction is represented by a wide spectrum of disease entities ranging from the asymptomatic virus carrier (ASC) to chronic hepati tis, cirrhosis, and hepatocellular carcinoma (2, 3) . Regular follow-up is important, especially in hepa-titis Be-antigen (HBeAg) posltlve patients because the virus is actively replicating in those patients and the patients undergo recurrent and progressive exacerbation of hepatic injury (4) (5) (6) .
Observing the natural course of the HBV carriers with positive HBeAg reveals the following cyclic patterns: normal liver function stage (ASC stage), gradual deterioration of the liver function, acute hepatitis-like hepatocellular damage (acute exacerbation stage), and recuperation (7) . Activation of the cellular immunity; mainly cytotoxic T cells, following viral replication is thought to play an important role in the mechanisms of this cyclic acute exacerbation of hepatocellular damage (S-13). Therefore, immunological monitoring of HBV carriers is clinically important to manage the patients and understand the relationship between HBY replication, activity of cellular immunity and hepatocellular damage.
Alanine amino transferase (ALT) and HBeAg are widely used as clinical indices for hepatocyte necrosis and viral replication, respectively However, there has not been an appropriate marker for the activated cellular immwlity, and there are few reports monitoring HBV carriers from immunological viewpoints.
~eopterin belongs to a group of pteridine compounds synthesized in vivo from guanosine triphmp h.He IGTP ) via GTP cyclohydrolase I ( 14) , and i~ produced mainly by activated macrophages tmder stimulation by interferon gamma (IFN-y) delivered from activated T-ceUs (15) . As a positive correlation bet\\'een increased serum neopterin levels and immune response has been reported in vivo and in \'i\'o ( 16), neopterin is widely recognized as a biolugical maker for the activated cell-mediated immunity (17) .
The aim of this study is to investigate the clinical course of HBY carriers with recurrent exacerbation of liver injury and their dynamic interaction between \,iral replication, cellular immunoreactivity and hepatocellular damage, focusing on serum neopterin monitoring.
Patients and Methods

Patients
Five adult chronic HBV carrier patients with both HBsAg and HBeAg-seropositivity were investigated in this study All of them were histologically diagnosed as chronic aClive hepatitis.
They were negative for anti-IgM HA, anti-delta, .1I1ti-human immunodeficiency virus, anti-HCV antibodies by the commercial serological tests and HCY- RNA by the reversetranscription polymerase chain reaction CRT-PCR) assay, and showed no evidence of alcoholic, autoimmune or drug-induced liver damage. None of these patients or Epstein-Barr virus, and received anti-viral or immunosuppressive therapy before is study.
In the present study, the period when the serum ALT levels were markedly elevated more than 300 IU /m!, was defined as "acute exacerbation of liver damage (AE) state". On the other hand, the period when the serum ALT levels were normal or nearly normal preceding or after AE period, was defined as "asymptomatic carrier (ASC) state".
If they needed anti-viral therapy during their investigated periods, they were treated with interferon beta ( IFN-~; Feron, Toray Industries, Inc., Tokyo, Japan) 6 MU per day intravenous administration for 4 consecutive weeks.
Informed consent was obtained from each patient before entry into the study.
Methods
They were followed by serial biochemical and serological tests at various time points of each ASC state and during the periods from two months before AE through the peak still two months after AE. At the same time, serial serum samples were also collected and were stored immediately at -3CJ'C for assay of serum neopterin levels, Serum ALT level was measured with a multi-channel autochemical analyzer (Hitachi 736-60E Hitachi Co., Ltd. , Tokyo, Japan) and expressed as international units per liter (IU/I).
HBeAg and antibody to HBeAg (HBeAb) were analyzed by using available commercial radioimmunoassays (RIAs; Dinabot Co., Ltd. ) and expressed as a cut-off index and percentage (%), respectively. HBV DNA polymerase, which is a direct indicator of HBV replication, was assayed by using an available commercial serological assay and expressed as cpm.
Serum neopterin level was measured by using a RIA kit "IMMU test N eopterin" (Henning Berlin GMBH, Berlin, Germany) . Radioactivity was counted by a programed gamma-counter "ANSR" (Dinabot Co.,Ltd.,Tokyo, Japan) and its value was expressed as nmol/l.
To determine the normal level of serum neopterin, forry five serum samples of health\' adult blood donors (25 men and 20 women. age ranged from 23 to 66 yyears, mean age of 42 ~'ears ) were assayed. The mean level of serum neopterin (mean±SE) was 4.4±0.S nmoll 1.f..3 ±0.7 nmol/L for the men and 4.S±0.8 nmol/l for the women, respectively). There were no signifIcant differences in the mean semm neopterin levels attributable to sex or age, thus suggesting that semm neopterin level dose not Huctuate between the sexes within this age range. Therefore, the mean levels of semm neopterin was used as normal level.
Comparison between mean values were determined by Student's test for paired data. A P value of <O.OS was considered as statistically significant.
Results
All the patients had initially both HBsAg and HBeAg in their semm. They were observed t()tmean eighteen months (from twelve months to twenty four months ) period and showed a cyclic pattern characterized by high ALT elevations (AE state) alternating with normal or nearly norrnalliver function (ASC state). In the follow up period, there were total fourteen times episodes of AE in Eve patients. Three (Table 1) .
Through the clinical course of each patient, their levels of semm neopterin changed dynamically related to those of HBeAg and ALI The result of a one-'ear follow up study by semm neopterin monitoring on a treatment-free patient (No.1 ) is shown in Figure 1 . This patient shows a cyclic pattern characterized by AE alternating with normal liver function during the study. The change of serwn neopterin was closely related to that of HBeAg and ALI The chronological changes in the levels of semm neopterin and HBV markers before and after AE on another patient (No.3 ) is shown in Figure 2 Figure 3 . In the patient, however HBeAb turned positive (100%) and HBeAg disappeared after 2S0 days of the study, an acute hepatocellular damage reoccurred after seroconversion. Because HBV-DNA polymerase level increased highly again even after HBeAg had diminished, it is suggested that this AE was caused by the mutant type of HBV Serwn neopterin changed in correlation with HBV-DNA polymerase and ALT even after disappearance of HBeAg.
According to the total of fourteen times episodes of AE in five patients, the detailed dynamics of HBeAg, serum neopterin and ALT levels preceding, during and after episodes of AE state were analyzed Figure 4 ). There were no significant differences in the mean level of serum neopterin between healthy subjects and those of patients at ASC state (4.4±0.8 nmol/l vs . 4.9±0.7 nmol/l, P>0.05 ). Two months befc)re AE, at ASC state with normal ALT level, no increase of serum neopterin could be detected. Then serum HBeAg increased gradually with an increase in serum neopterin level 4 weeks before AE. Concurrently, rapid destruction of hepatocytes occurred (i.e., the peak of AE) with high levels of serum neopterin. Two weeks after the peak of AE, HBeAg was significantly reduced already and the hepatocellular damage diminished as the neopterin level . decreased.
Discussion
The present study showed that the levels of serum neopterin changed dynamically related to those of HBeAg and ALT following chronic hepatitis B patients. This data suggest that serum neopterin monitoring enabled to observe the interaction between HBV replication and hepatocellular damage in terms of the activity of cellular immunity Many hepatitis B patients with positive HBe antigen (HBeAg), when observed for long periods, undergo recurrent acute hepatitis-like liver dysfunction intermitted by periods without hepatocellular dagame (4-6). The hepatitis B vim'> is not directly cytopathic for the infected hepatocyte, and HBVspecific liver cell injury and subsequent viral clearance is though to be mediated by immune mechanisms (9, 18) . Recently, both increased proliferation and interferon gamma (IFN-y) production in response to HBeAg or HBcAg was reported during AE of chronic hepatitis B patients (18) (19) (20) . In addi-tion, AE and the seroconversion to anti-HBe in both chronic and acute HBV infection are associated with an elevated production of INF-y by PBMC upon stimulation with HBeAg or HBcAg (21 ) . On the other hand, neopterin is widely recognized an indicator for activation of cellular immunity, for endogenous IFN -y production and for monocyte/ macrophage activation (16, 22) . Theretore, it is reasonable to monitor serum neopterin level serially along with markers for h epatocyte necrosis and viral replication to follow-up HBV carriers with recurrent AE.
The results of our kinetic studies on HBeAg, neopterin, and ALT relative to AE demonstrated a close involvement of viral replication prior to acute liver injury as well as an activation of the cellular immunity following the viral replication. The detailed mechanisms of AE in HBV carriers are yet to be elucidated (4, 6, 18, 23) . Previous reports suggested a cascade of mechanisms as follows; at first, something triggers viral replication resulting in an imbalance of immunity, the this imbalance o f immunity induces activation of the cellular immunity~ mainly cytotoxic T cells w hich destroy the infected hepatocytes eliminating the virus. Although the first trigger causing HBV replication has not been known yet, the present study shows that serum neopterin monitoring is helpful to understand the relation between the the cellular immunity, hepatocellular damage and HBY replication according to AE in HBV carriers.
It is known that liver damage in HEV carriers subsides following seroconversion from HEeAg positivity to HBe antibody (HBeAb) positivity (7, 24, 25 ) . However, it has been recently reported that mutant HBY causes liver injury which persists even after the seroconversion to HBeAb positivity,: In the present study, the mutant HBV replication with AE after seroconversion was found in one of the patients, and the serum neopterin level in this patient was high along w ith the liver damage. This suggests that liver damage induced by HBV mutant type as well as HBV wild ty'pe closely relates to the activated cellular immunity; and it is possible to monitor hepatitis B virus carriers in terms of cellular immunity independently o f HBeAg positive or negative by measuring serum neopterin level.
lliterferon is widely used for the treatment of chronic hepatitis B. The efficiency of IFN was influenced by some factors such as age, sex, HBV load, histological findings of liver biopsy. The cellular immune response is also thought to be one of the important factors for successful IFN treatment. In this study, the patients treated with IFN-f3 showed 211 high levels of serum neopterin throughout the treatment. This suggests the possibility that IFN-f3 directly or indirectly through a cytokine network affects the cellular immwlity. Therefore, serum neopterim monitoring may be applied to estimate the etlects and the reversed effects of IFN therapy. This intriguing possibility requires further investigation.
In conclusion, this study shows the clinical usefulness of serum neopterin as an index tor monitoring HBV carriers with recurrent exacerbation of liver damage. Serum neopterin monitoring could provid: immunological information about the dynamic interaction between HEV replication, cellular immunoactivity and liver injury. Serum neopterin may represent to be a complementary marker to follow and manage chronic hepatitis B patients.
